Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Andreeff

Showing results (171-180 of 504) with videos related to

Pageof 51
Sort By:
Cancer Research|November 4, 2005
Development of a conditional in vivo model to evaluate the efficacy of small molecule inhibitors for the treatment of Raf-transformed hematopoietic cellsMarina Konopleva, Yuexi Shi, Linda S Steelman, et al.
Human Gene Therapy|April 30, 2003
Bystander transfer of functional human CD40 ligand from gene-modified fibroblasts to B-chronic lymphocytic leukemia cellsEttore Biagi, Eric Yvon, Gianpietro Dotti, et al.
Cancer|February 23, 2007
Overexpression of CXCR4 predicts adverse overall and event-free survival in patients with unmutated FLT3 acute myeloid leukemia with normal karyotypeSergej Konoplev, Georgios Z Rassidakis, Elihu Estey, et al.
Cell Cycle (Georgetown, Tex.)|December 19, 2006
Studying the right cell in acute myelogenous leukemia: dynamic changes of apoptosis and signal transduction pathway protein expression in chemotherapy resistant ex-vivo selected "survivor cells"Steven M Kornblau, Yi Hua Qiu, B N Bekele, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 17, 2013
CXC chemokine receptor 4 expression, CXC chemokine receptor 4 activation, and wild-type nucleophosmin are independently associated with unfavorable prognosis in patients with acute myeloid leukemiaSergej Konoplev, Pei Lin, C Cameron Yin, et al.
Cytotherapy|March 17, 2010
Mesenchymal stromal cells alone or expressing interferon-beta suppress pancreatic tumors in vivo, an effect countered by anti-inflammatory treatmentShannon Kidd, Lisa Caldwell, Martin Dietrich, et al.
Molecular Cancer Therapeutics|April 18, 2014
Evaluation of apoptosis induction by concomitant inhibition of MEK, mTOR, and Bcl-2 in human acute myelogenous leukemia cellsWeiguo Zhang, Vivian R Ruvolo, Chen Gao, et al.
Haematologica|October 19, 2010
Phase I study of sorafenib in patients with refractory or relapsed acute leukemiasGautam Borthakur, Hagop Kantarjian, Farhad Ravandi, et al.
Cancer|June 25, 2005
2-Chlorodeoxyadenosine and cytarabine combination therapy for idiopathic hypereosinophilic syndromeElias Jabbour, Srdan Verstovsek, Francis Giles, et al.
Journal of the National Cancer Institute|January 31, 2008
Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemiaWeiguo Zhang, Marina Konopleva, Yue-xi Shi, et al.
Pageof 51

Showing results (171-180 of 504) with videos related to

Sort By:
Pageof 51
Cancer Research|November 4, 2005
Development of a conditional in vivo model to evaluate the efficacy of small molecule inhibitors for the treatment of Raf-transformed hematopoietic cellsMarina Konopleva, Yuexi Shi, Linda S Steelman, et al.
Human Gene Therapy|April 30, 2003
Bystander transfer of functional human CD40 ligand from gene-modified fibroblasts to B-chronic lymphocytic leukemia cellsEttore Biagi, Eric Yvon, Gianpietro Dotti, et al.
Cancer|February 23, 2007
Overexpression of CXCR4 predicts adverse overall and event-free survival in patients with unmutated FLT3 acute myeloid leukemia with normal karyotypeSergej Konoplev, Georgios Z Rassidakis, Elihu Estey, et al.
Cell Cycle (Georgetown, Tex.)|December 19, 2006
Studying the right cell in acute myelogenous leukemia: dynamic changes of apoptosis and signal transduction pathway protein expression in chemotherapy resistant ex-vivo selected "survivor cells"Steven M Kornblau, Yi Hua Qiu, B N Bekele, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 17, 2013
CXC chemokine receptor 4 expression, CXC chemokine receptor 4 activation, and wild-type nucleophosmin are independently associated with unfavorable prognosis in patients with acute myeloid leukemiaSergej Konoplev, Pei Lin, C Cameron Yin, et al.
Cytotherapy|March 17, 2010
Mesenchymal stromal cells alone or expressing interferon-beta suppress pancreatic tumors in vivo, an effect countered by anti-inflammatory treatmentShannon Kidd, Lisa Caldwell, Martin Dietrich, et al.
Molecular Cancer Therapeutics|April 18, 2014
Evaluation of apoptosis induction by concomitant inhibition of MEK, mTOR, and Bcl-2 in human acute myelogenous leukemia cellsWeiguo Zhang, Vivian R Ruvolo, Chen Gao, et al.
Haematologica|October 19, 2010
Phase I study of sorafenib in patients with refractory or relapsed acute leukemiasGautam Borthakur, Hagop Kantarjian, Farhad Ravandi, et al.
Cancer|June 25, 2005
2-Chlorodeoxyadenosine and cytarabine combination therapy for idiopathic hypereosinophilic syndromeElias Jabbour, Srdan Verstovsek, Francis Giles, et al.
Journal of the National Cancer Institute|January 31, 2008
Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemiaWeiguo Zhang, Marina Konopleva, Yue-xi Shi, et al.
Pageof 51